Published in Hospital Law Weekly, November 16th, 2006
According to recent research published in the International Journal of Radiation Oncology Biology Physics, "Permanent IB has become an increasingly appealing therapeutic option for LPC among physicians and patients because it involves short hospitalization and treatment and its postulated low degree of toxicity may reduce its impact on the patients' QoL. The aim of this prospective study was to assess the impact of IB on the QoL of patients...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.